📊 ADCT Key Takeaways
Is ADC Therapeutics SA (ADCT) a Good Investment?
ADC Therapeutics exhibits severe fundamental distress with negative stockholders' equity (-$216.4M) and persistent cash burn (-$29.7M operating FCF), indicating the company is technically insolvent on a balance sheet basis. While revenue is growing (+14.9% YoY) and losses are improving, the company is not yet viable as a standalone entity without additional financing or dramatic operational improvement.
ADC Therapeutics shows some top-line momentum, with revenue up 14.9% year over year and a strong liquidity position in the near term, but the business remains deeply unprofitable with operating and free cash flow losses that far exceed its revenue base. Negative equity, weak interest coverage, and sustained cash burn indicate that current growth quality is poor and the balance sheet leaves little room for execution missteps.
Why Buy ADC Therapeutics SA Stock? ADCT Key Strengths
- Revenue growth of 14.9% YoY demonstrates commercial traction and product adoption
- EPS losses improving 30.9% YoY indicates operational efficiency gains and progress toward breakeven
- Strong cash position of $231M and excellent liquidity ratios (4.09x current) provide ~7-8 year runway at current burn rate
- Revenue is growing at a double-digit rate year over year
- Cash and equivalents of $261.34M support near-term liquidity
- Current and quick ratios above 4x indicate strong short-term balance sheet liquidity
ADCT Stock Risks: ADC Therapeutics SA Investment Risks
- Negative stockholders' equity of -$216.4M: liabilities exceed assets, indicating technical insolvency and extreme financial distress
- Persistent negative operating cash flow (-$29.7M) means company must rely on cash reserves; not self-sustaining without profitability achievement
- Operating margin of -121% and net margin of -158% show company spends $2.58 to generate $1 of revenue; path to profitability unclear
- Operating margin of -149.3% and net margin of -175.3% show an unsustainably unprofitable cost structure
- Negative free cash flow of $141.44M implies continued cash burn and potential future financing needs
- Negative stockholders equity and negative interest coverage reflect a stressed capital structure
Key Metrics to Watch
- Operating cash flow trend: must turn positive within 24 months for viability
- Revenue growth acceleration and gross margin realization as sales scale
- Stockholders' equity trajectory: negative equity must reverse through sustained profitability or external financing
- Quarterly cash burn relative to cash balance
- Revenue growth versus operating loss trajectory
ADC Therapeutics SA (ADCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.09x current ratio provides a solid financial cushion.
ADCT Profit Margin, ROE & Profitability Analysis
ADCT vs Healthcare Sector: How ADC Therapeutics SA Compares
How ADC Therapeutics SA compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ADC Therapeutics SA Stock Overvalued? ADCT Valuation Analysis 2026
Based on fundamental analysis, ADC Therapeutics SA has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ADC Therapeutics SA Balance Sheet: ADCT Debt, Cash & Liquidity
ADCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ADC Therapeutics SA's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.62 indicates the company is currently unprofitable.
ADCT Revenue Growth, EPS Growth & YoY Performance
ADCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.4M | -$33.0M | $-0.21 |
| Q3 2025 | $15.8M | -$41.0M | $-0.30 |
| Q2 2025 | $17.0M | -$36.5M | $-0.38 |
| Q1 2025 | $17.4M | -$38.6M | $-0.36 |
| Q3 2024 | $14.3M | -$44.0M | $-0.42 |
| Q2 2024 | $17.0M | -$36.5M | $-0.38 |
| Q1 2024 | $17.8M | -$46.6M | $-0.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ADC Therapeutics SA Dividends, Buybacks & Capital Allocation
ADCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ADC Therapeutics SA (CIK: 0001771910)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADCT
What is the AI rating for ADCT?
ADC Therapeutics SA (ADCT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADCT's key strengths?
Claude: Revenue growth of 14.9% YoY demonstrates commercial traction and product adoption. EPS losses improving 30.9% YoY indicates operational efficiency gains and progress toward breakeven. ChatGPT: Revenue is growing at a double-digit rate year over year. Cash and equivalents of $261.34M support near-term liquidity.
What are the risks of investing in ADCT?
Claude: Negative stockholders' equity of -$216.4M: liabilities exceed assets, indicating technical insolvency and extreme financial distress. Persistent negative operating cash flow (-$29.7M) means company must rely on cash reserves; not self-sustaining without profitability achievement. ChatGPT: Operating margin of -149.3% and net margin of -175.3% show an unsustainably unprofitable cost structure. Negative free cash flow of $141.44M implies continued cash burn and potential future financing needs.
What is ADCT's revenue and growth?
ADC Therapeutics SA reported revenue of $20.9M.
Does ADCT pay dividends?
ADC Therapeutics SA does not currently pay dividends.
Where can I find ADCT SEC filings?
Official SEC filings for ADC Therapeutics SA (CIK: 0001771910) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADCT's EPS?
ADC Therapeutics SA has a diluted EPS of $-0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ADCT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, ADC Therapeutics SA has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ADCT stock overvalued or undervalued?
Valuation metrics for ADCT: ROE of N/A (sector avg: 15%), net margin of -158.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ADCT stock in 2026?
Our dual AI analysis gives ADC Therapeutics SA a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADCT's free cash flow?
ADC Therapeutics SA's operating cash flow is $-29.7M, with capital expenditures of $32.0K. FCF margin is -142.6%.
How does ADCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -158.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.09 (avg: 2).